CONX Stock News Corgenix Med Corp (CONX) 0.3193 07/25/2014 0

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Corgenix Med Corp (CONX) 0.3193 $CONX

Corgenix Joins Strategic Partners, Presents Science at AACC Meeting and Clinical Lab Expo 2014
Business Wire - Tue Jul 22, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners and also present several scientific abstracts at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago.

Corgenix enters into technology transfer & product development agreement for Mellitussfor gestational diabetes test GCD59
M2 - Tue Jul 15, 8:29AM CDT
Diagnostic test kits company Corgenix Medical (Other OTC:CONX) on Monday launched a technology transfer and product development agreement with Mellitus in support of clinical research and product commercialisation.

Corgenix Signs Technology Transfer, Product Development Agreement with Mellitus LLC for Gestational Diabetes Test
Business Wire - Mon Jul 14, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)

Corgenix, Research Group Announce NIH Grant to Advance Work on Ebola Rapid Diagnostic Test Kit
Business Wire - Thu Jun 26, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded a three-year, $2.9 million National Institutes of Health (NIH) grant to advance the development of an Ebola rapid diagnostic test kit. Collaborating with Corgenix on the program will be members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University and partially funded with support from the NIH.

Corgenix Announces CE Mark Notification for TxBCardio(TM) Assay
Business Wire - Thu May 15, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB) announced in collaboration with Randox Laboratories that Randox has been granted CE Mark notification for its TxBCardio(TM) Assay. The TxBCardio test measures urinary levels of the thromboxane metabolite 11dhTxB2 to determine aspirin effect in apparently healthy individuals. CE mark designation enables commercial marketing and distribution of the product in Europe.

Corgenix Reports Third Quarter Fiscal 2014 Financial Results
Business Wire - Thu May 15, 8:02AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its third-quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues and net income increased for the year to date. Highlighted results of the report include:

Corgenix, Tulane and Viral Hemorrhagic Fever Consortium Publish Promising Results from Lassa Fever Trial
Business Wire - Tue Apr 01, 8:15AM CDT
A Corgenix Medical (OTCBB:CONX) rapid diagnostic test (RDT) for the dangerous Lassa fever virus has demonstrated the ability to quickly detect the virus, responsible for the deaths of thousands and infection of hundreds of thousands in West Africa each year. That's according to the results of the five-year trial Lassa Fever in Post-Conflict Sierra Leone published in the PLOS Neglected Tropical Diseases Journal.

Corgenix and Research Partners to Expand Ebola Virus Testing Capabilities in Sierra Leone
Business Wire - Thu Mar 27, 8:15AM CDT
An outbreak of the deadly Ebola virus in West Africa has prompted Corgenix Medical Corporation (OTCBB:CONX) to extend its existing viral hemorrhagic fever (VHF) rapid test development to include the Ebola virus. Corgenix has already developed and CE marked a rapid test for the Lassa fever virus, another member of the VHF group of viruses.

Corgenix Board of Directors Announces Exploration of Strategic Alternatives
Business Wire - Wed Mar 12, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that the Company's Board of Directors has decided to explore strategic alternatives to enhance value for shareholders. These alternatives could include, among others, possible joint ventures, strategic partnerships or alliances, a sale of the Company or other possible transactions.

Corgenix Medical Corporation posts higher net income of USD178,497 for Q2 fiscal 2014
M2 - Fri Feb 14, 3:06AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTC BB:CONX) reported on Thursday its net income of USD178,497 for second quarter fiscal 2014.

Corgenix Reports Second Quarter Fiscal 2014 Financial Results
Business Wire - Thu Feb 13, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues and net income increased both for the quarter and year to date. Some of the results highlighted by the report are as follows:

Corgenix to Host Conference Call to Discuss Second Quarter Results
Business Wire - Tue Feb 04, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, February 13, 2014, at 4:00 p.m. EST to discuss the Company's financial and operating performance for its quarter ended December 31, 2013, and the status of the Company's product development and marketing activities.

Corgenix Announces Filing of 510(k) Premarket Notification for FDA Clearance of TxBCardio(TM) Assay
Business Wire - Mon Dec 16, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX.OB) announced today that in collaboration with Randox Laboratories, the first premarket notification has been filed with the U.S. Food and Drug Administration pursuant to Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act for the TxBCardio(TM) immunoturbidimetric (IT) assay.

Corgenix to Host Conference Call to Discuss Fiscal 2013 Results
Business Wire - Wed Sep 18, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company's financial and operating performance for its fiscal year ended June 30, 2013, and the status of the Company's product development and marketing activities.

Corgenix Medical Corporation renews agreement with Dr Matsuura and retains right to the AtherOx technology
M2 - Wed Sep 11, 9:38AM CDT
Diagnostic kits company Corgenix Medical Corporation (OTCQB:CONX.OB) reported on Tuesday the execution of a new AtherOx License and Cooperation Agreement with Dr Eiji Matsuura of Okayama, Japan.

Corgenix Medical Corporation Announces New AtherOx(R) (Oxidized LDL Technology) License and Cooperation Agreement
Business Wire - Tue Sep 10, 8:15AM CDT
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx(R) License and Cooperation Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan. Concurrently with the execution of the new agreement, Dr. Matsuura terminated his arbitration demand of June 28, 2013 related to the April 14, 2010 Amended and Restated License Agreement between the parties.

Corgenix Medical Corporation reports new USD1.5m revolving credit facility, with favorable interest rate and greater flexibility
M2 - Thu Sep 05, 6:29AM CDT
Diagnostic test kits company Corgenix Medical Corporation (OTCQB:CONX.OB) revealed on Wednesday the completion of a USD1.5m secured revolving line of credit with Bank of the West.

Corgenix Medical Corporation Announces New $1.5 Million Revolving Credit Facility
Business Wire - Wed Sep 04, 8:15AM CDT
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced that it has closed on a $1.5 million secured revolving line of credit with Bank of the West. The new revolving line of credit provides Corgenix a very favorable interest rate and much greater flexibility than the previous asset-based revolving line of credit. The new credit facility follows the recent move by Corgenix of its primary banking arrangements to Bank of the West.

OTC Daily Alert Stock Watch - Corgenix (OTCQB: CONX)
WorldStockWire - Tue Aug 27, 7:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BETR's Legal Tangle: A Deeper Dive into Investor Turmoil

Updated Category News Views 157

BETR's Shaky Ground: When Promises Fall Short In the rough-and-tumble world of finance, there's little room for empty promises. Better Home & Finance Holding Company (NASDAQ: BETR) might have to learn that the hard way. Investors who snagged shares between March 13 and August 6, 2026, are now clutching their heads as they watch their investments nosedive. When companies...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Local Bounti Expands: Acquires CEA Facilities

Updated Category News Views 72

Local Bounti's Strategic Acquisition Move Local Bounti's at it again, shaking up the indoor agriculture scene by snapping up some real estate from Revol Greens. We're talking 30 acres of primo certified-organic greenhouse space across Texas and Minnesota. And they’re picking these babies up right as they’re ready to grow, not like some flashy land grab. Digging into...

Continue Reading
EUBG Faces Tough Third Quarter Amid Challenges

Updated Category News Views 187

What's Happening with EUBG? Entrepreneur Universe Bright Group, better known in the markets as EUBG, is navigating some choppy waters if their recent financial numbers are anything to go by. You'd think companies boasting a digital-focused strategy would be printing money in today's tech-driven world, but EUBG's third quarter of 2026 has a different story to tell. The...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 87

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 194

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 49

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 168

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading

Top 5 Most Recently Viewed Articles

Nauticus Robotics Reports Exciting Q3 2025 Financial Results

Updated Category News Views 251

Nauticus Robotics Shows Strong Performance in Q3 2025 Nauticus Robotics, Inc. (NASDAQ: KITT), an industry leader in subsea robotics, has recently made headlines with their impressive financial performance during the third quarter of 2025. This period marked a remarkable increase in customer interest, innovative capabilities, and upcoming product launches that promise to...

Continue Reading
Nano Labs' Strategic Move to Nasdaq Global Market: Key Benefits

Updated Category News Views 152

Nano Labs Elevates to Nasdaq Global Market Nano Labs Ltd (Nasdaq: NA), a frontrunner in Web 3.0 infrastructure and product solutions, has officially announced its uplisting to the Nasdaq Global Market. This significant move is designed to provide enhanced opportunities for growth and stability, marking an exciting chapter for the company and its shareholders. Impact of...

Continue Reading
The EVERY Company Strengthens Its Patent Portfolio in Europe

Updated Category News Views 169

The EVERY Company Enhances Its Intellectual Property The EVERY Company, a prominent innovator in protein ingredients, has recently secured a significant patent for its recombinant ovalbumin in the European Union. This development consolidates its position as a leader in crafting functional protein ingredients, paving the way for its growth and expansion within the global...

Continue Reading
Discover the Compounding Success of Analog Devices Over a Decade

Updated Category News Views 204

How $100 Invested in Analog Devices Transformed Over 10 Years Analog Devices (NASDAQ: ADI) has had a remarkable journey over the past decade, outperforming the market with an annualized growth of 2.67%, resulting in an impressive average annual return of 14.15%. As of the latest figures, Analog Devices boasts a market capitalization of approximately $118.16 billion. The...

Continue Reading
Mustang Bio Secures $8 Million in Public Offering Success

Updated Category News Views 118

Mustang Bio Completes $8 Million Public Offering Mustang Bio, Inc. (Nasdaq: MBIO), a prominent company in the biopharmaceutical sector, renowned for its innovative cell therapies, recently announced the successful closure of a public offering that raised approximately $8 million. This financial milestone signifies a major step forward for the company as it aims to drive...

Continue Reading